Abivax is trading 4.14% lower at $88.55, amid weakness across the biotech sector. - XBI was down 2.06% during the regular session. - STAT News has reported a broader recent retreat among biotech investors. - Abivax’s seven obefazimod abstracts are scheduled for UEG Week beginning October 17; they were not a new announcement on October 16.